Ardent Health Partners, Inc. - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Ardent Health Partners, Inc. (Ardent) operates 30 acute care hospitals across six states (Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas). On July 17, 2024, the company converted from a limited liability company to a Delaware corporation and completed its Initial Public Offering (IPO) on July 19, 2024, listing on the NYSE under the symbol "ARDT".
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $1,449.8 million | $1,377.7 million | $4,359.8 million | $4,063.4 million |
| Net Income (GAAP) | $46.0 million | $38.7 million | $158.8 million | $118.2 million |
| Net Income Attributable to Ardent | $26.3 million | $20.8 million | $96.1 million | $58.1 million |
| Diluted EPS | $0.19 | $0.17 | $0.74 | $0.46 |
| Adjusted EBITDA | $97.8 million | $84.8 million | $315.9 million | $256.4 million |
| Adjusted EBITDAR | $137.8 million | N/A | $435.7 million | N/A |
| Cash and Cash Equivalents | $563.1 million | $444.7 million (End of Q3 2023) | $563.1 million | $444.7 million |
| Total Debt (Carrying Value) | $1,095.9 million | $1,186.9 million (Dec 31, 2023) | $1,095.9 million | $1,186.9 million |
| Operating Cash Flow (YTD) | N/A | N/A | $195.5 million | $154.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5.2% in Q3 and 7.3% YTD compared to the prior year periods. This was driven by a 6.4% increase in admissions and a favorable payer mix, partially offset by a strategic reduction in low-margin outpatient surgeries.
- Profitability: Net income attributable to Ardent increased 26.3% in Q3 and 65.6% YTD. Operating expenses as a percentage of revenue decreased due to reduced contract labor costs and supply chain efficiencies.
- Debt Management: The company prepaid $100.0 million of its Term Loan B Facility in June 2024. In September 2024, the company repriced the Term Loan B Facility, reducing the interest rate by 50 basis points (from Term SOFR + 3.25% to Term SOFR + 2.75%).
- Capital Structure: The company raised approximately $208.7 million in net proceeds from its IPO and the exercise of the underwriters' option in July 2024.
Guidance, Outlook, and Risks
- Cybersecurity Incident: A November 2023 ransomware attack caused an estimated $74 million pre-tax impact in 2023. While operations are no longer materially disrupted, billing delays persisted into Q1 2024. A consolidated class action lawsuit regarding the incident was settled in October 2024, with payments expected to have no material impact on financial results.
- Regulatory Outlook: The company anticipates a material rate uplift from the New Mexico Healthcare Delivery and Access Act (pending CMS approval) and has recognized $48.6 million in revenue from the new Oklahoma Directed Payment Program. Management estimates a combined annualized net benefit of over $150 million from these programs.
- Liquidity: As of September 30, 2024, available liquidity totaled $851.2 million, comprising $563.1 million in cash and $288.1 million in available capacity under the amended ABL Credit Agreement.
- Risks: Key risks include labor shortages, inflationary pressures on wages and supplies, regulatory changes in Medicare/Medicaid reimbursement, and the impact of the No Surprises Act on out-of-network billing.
Investor Verification Checklist
- IPO Proceeds Utilization: Verify the deployment of the ~$209 million in net IPO proceeds against the stated capital allocation strategy.
- Cybersecurity Costs: Monitor ongoing litigation costs and insurance recoveries related to the 2023 ransomware incident to ensure the "no material impact" assessment holds.
- Regulatory Approvals: Track the status of the New Mexico HDA Act approval by CMS, as this is a key driver for future revenue growth.
- Debt Covenants: Review compliance with the Ventas Master Lease covenants (minimum portfolio coverage ratio of 2.2x) and the Senior Secured Credit Facilities.
- Noncontrolling Interests: Analyze the portion of net income attributable to noncontrolling interests (approx. 43% of total net income) and the terms of the joint venture agreements.